Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 9, 2025Open Access

Beyond amyloid and tau: synaptic and neurodegenerative biomarkers shape MCI progression

View Full Paper
Ask AI
Bookmark
Share

Authors

CDConstance DelabySSSusanna Schraen‐MaschkeCPClaire Paquet

Discussion

Loading...

Member takes

Overview

Prospective analysis identifies neurodegenerative and synaptic biomarkers in MCI patients, indicating better prognosis than amyloid markers.

Key Points

  • 63% of mild cognitive impairment patients converted to Alzheimer disease within three years.
  • CSF markers like tau and NfL showed better prognostic accuracy for conversion than plasma p-tau biomarkers.
  • The combination of IL-16, tau, and NPTX2 in CSF achieved a high prognostic accuracy with an AUC of 0.86.
  • Effective assessment of MCI progression relies on multiple biomarkers reflecting both neurodegeneration and synaptic dysfunction.

Cite This Study

Delaby et al. (2025) studied this question.

synapsesocial.com/papers/68e70db790569dd607ee67f9https://doi.org/10.1101/2025.10.06.25337445
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Plasma Phosphorylated Tau217–A Pivotal Plasma Biomarker for Predicting the Progression of Mild Cognitive Impairment to Alzheimer’s Disease: A Reanalysis of ADNI Data2026 · 1 citations
  2. 2Progress in prognostic assessment methods for mild cognitive impairment2026
  3. 3Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi‐cohort study2023 · 48 citations
  4. 4Prediction of mild cognitive impairment progression using time-sensitive multimodal biomarkers2025
  5. 5Predicting Longitudinal Cognitive Decline and Alzheimer’s Conversion in Mild Cognitive Impairment Patients Based on Plasma Biomarkers2024 · 16 citations